COMP <GO>
BDX vs BSX // EV/EBITDA & P/E VALUATION
Becton Dickinson and Company (NYSE) VS. Boston Scientific Corporation (NYSE) • 15-METRIC TALLY: BDX 3
— BSX 10
▲ EV/EBITDA & P/E VALUATION LEADER: BSX
LAST: $197.88 (-0.23%) • MKT CAP: $54.03B
valuation
21.8x
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
valuation
15.8x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BDX VS. BSX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BDX | BSX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 45.40% | 69.00% | -23.60 | BSX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 4.90% | 9.20% | -4.30 | BSX | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.8x | 15.8x | +6.00 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 2.13% | 5.91% | -3.78 | BSX | /fcf-yield <GO> |
| Operating Margin | 11.80% | 18.00% | -6.20 | BSX | /operating-margins <GO> |
| Net Profit Margin | 7.70% | 14.00% | -6.30 | BSX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.20% | 19.90% | -11.70 | BSX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.21% | 0.00% | +2.21 | BDX | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.22 | 2.77 | -0.55 | BSX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 8/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 64.6 | 43.0 | +21.60 | BDX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 0.99 | +0.07 | BDX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 29.9x | 18.5x | +11.40 | BSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $54.03B | $61.87B | -$7.84B | BSX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BDX REV | BSX REV | BDX GROSS % | BSX GROSS % | BDX FCF | BSX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $21.84B | $20.07B | 45.4% | 69.0% | — | $3.66B |
| FY 2024 | $20.18B | $16.75B | 45.2% | 68.6% | — | $2.65B |
| FY 2023 | $19.37B | $14.24B | — | — | — | $1.86B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BDX // BETA 1.06
BSX // BETA 0.99